Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Convertible Debt (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Convertible Debt for 11 consecutive years, with $199.2 million as the latest value for Q1 2025.

  • Quarterly Convertible Debt changed 0.34% to $199.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $199.2 million through Mar 2025, changed 0.34% year-over-year, with the annual reading at $199.0 million for FY2024, 0.34% changed from the prior year.
  • Convertible Debt hit $199.2 million in Q1 2025 for Ironwood Pharmaceuticals, roughly flat from $199.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $436.1 million in Q1 2021 to a low of $198.0 million in Q2 2023.
  • Historically, Convertible Debt has averaged $294.3 million across 5 years, with a median of $329.2 million in 2021.
  • Biggest five-year swings in Convertible Debt: increased 20.14% in 2022 and later tumbled 49.96% in 2024.
  • Year by year, Convertible Debt stood at $337.3 million in 2021, then grew by 17.47% to $396.3 million in 2022, then tumbled by 49.95% to $198.3 million in 2023, then rose by 0.34% to $199.0 million in 2024, then grew by 0.09% to $199.2 million in 2025.
  • Business Quant data shows Convertible Debt for IRWD at $199.2 million in Q1 2025, $199.0 million in Q4 2024, and $198.8 million in Q3 2024.